2500 participants
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-07-13
- Start Date:
- 2022-12-27
- Completion:
- 2027-12-30
Conditions
- Atrial Fibrillation (AF)
Interventions
- BIOLOGICAL
- DRUG
No Results Yet